TrialJournal of cancer research and clinical oncology2021

Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.

Yuan Zong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.